First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.

Original languageEnglish (US)
Pages (from-to)840-843
Number of pages4
JournalOncologist
Volume23
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Paclitaxel
Adenocarcinoma
Programmed Cell Death 1 Receptor
Drug Therapy
Esophagogastric Junction
Neoplasms
Stomach
Observation
Ligands
Pharmaceutical Preparations
ramucirumab
pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{43386c746eca49e58462635676a4f6f8,
title = "First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma",
abstract = "Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.",
author = "Sakti Chakrabarti and Dong, {Haidong M} and Harshita Paripati and Ross, {Helen J} and Yoon, {Harry H}",
year = "2018",
month = "7",
day = "1",
doi = "10.1634/theoncologist.2017-0561",
language = "English (US)",
volume = "23",
pages = "840--843",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma

AU - Chakrabarti, Sakti

AU - Dong, Haidong M

AU - Paripati, Harshita

AU - Ross, Helen J

AU - Yoon, Harry H

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.

AB - Checkpoint inhibitors targeted at programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) can result in significant benefit to a small proportion of patients with cancer, including those with tumors of the stomach and gastroesophageal junction. These drugs are now approved for several solid tumors, including the recent accelerated approval of pembrolizumab for gastroesophageal adenocarcinomas in the third-line setting and beyond based on the KEYNOTE-059 phase II trial. Data are lacking on the efficacy of chemotherapy after progression on PD-1 blockade in metastatic gastroesophageal adenocarcinoma. This report describes the exceptional response of two patients who received ramucirumab plus paclitaxel after progressive disease on pembrolizumab. This early clinical observation suggests that the sequence of administration of PD-1 blockade and chemotherapy may be important in this disease.

UR - http://www.scopus.com/inward/record.url?scp=85050506456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050506456&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0561

DO - 10.1634/theoncologist.2017-0561

M3 - Article

VL - 23

SP - 840

EP - 843

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -